Edesa Biotech (NASDAQ:EDSA) Posts Earnings Results, Misses Expectations By $0.17 EPS

Edesa Biotech (NASDAQ:EDSA) posted its quarterly earnings data on Friday. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.17), Zacks reports. During the same quarter last year, the company earned ($0.54) EPS.

Edesa Biotech Price Performance

EDSA opened at $2.69 on Friday. The business’s 50-day moving average price is $1.88 and its two-hundred day moving average price is $3.12. Edesa Biotech has a 1 year low of $1.55 and a 1 year high of $5.99.

Edesa Biotech Company Profile

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.